Somaxon Pharmaceuticals Inc

Somaxon Pharmaceuticals — Technical Presentation (June 2008)

6 slides from Somaxon Pharmaceuticals's technical presentation, Jun 12, 2008

  1. Slide 1: Figure 2. CGI-Improvement at Baseline, After 2 Weeks and After 12 Weeks

    Note: Severity categories included: Normal, Very Mild, Mild, Moderate, Marked, Severe, and Extremely Severe. Figure 2. CGI-Improvement at Baseline, After 2 Weeks and After 12 Weeks (Study A)

  2. Slide 2: Figure 3. % of Subjects on CGI-Improvement with Moderate to Marked Improvement

    Note: Improvement categories included: Marked Improvement, Moderate Improvement, Minimal Improvement, Unchanged, Minimal Worsening, Moderate Worsening, and Marked Worsening. Figure 3. % of Subjects on CGI-Improvement with Moderate to Marked Improvement (Study A)

  3. Slide 3: Figure 4. PGI Items After 12 Weeks

    Figure 4. PGI Items After 12 Weeks (Study A)

  4. Slide 4: Figure 5. % of Subjects on PGI Indicating Study Medication Helped Sleep

    Figure 5. % of Subjects on PGI Indicating Study Medication Helped Sleep (Study A)

  5. Slide 5: Figure 6. PGI Items at Final Study Visit (Study B)

    Figure 6. PGI Items at Final Study Visit (Study B)

  6. Slide 6: Safety Results

    SAFETY RESULTS Rates of treatment-emergent AEs were comparable across groups in both Study A (PBO=52%; DXP 1 mg=40%; DXP 3 mg=38%) and Study B (PBO=27%; DXP 6 mg=31%). There were two AEs reported by ³ 5% of subjects, headache in Study A (PBO=14%; DXP 1 mg=3%; DXP 3 mg=6%) and somnolence/sedation in

Somaxon Pharmaceuticals — Technical Presentation (June 2008) on 6ix